FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why

Vandana Singh
1 min read
0
In this article:

  • The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors.

  • The company's Phase 1 trial began enrolling patients in December 2020 and, in recent months, was exploring higher doses to define a maximum tolerated dose.

  • Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the company paused the enrollment of new patients to assess these adverse events further.

  • Also Read: FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors.

  • While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.

  • The company says that with $737.7 million in cash, it is well-positioned to continue developing all of its internal product candidates.

  • The company will provide updates on the direction of the NUV-422 program after it has completed its internal risk-benefit analysis, which will factor in feedback from FDA.

  • Price Action: NUVB shares are down 7.04% at $3.88 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories